| | Home | Back To Index | |
|
|
|||||||||||||||
|
This report reviews, analyzes and sizes the generic and biogeneric drug markets, particularly focusing on new biogeneric medicines. This report assesses the generic prescription market and maps the competitive landscape. The market forecast section sizes the market and discusses the five-year revenue projection to 2013. The market is segmented by key therapeutic applications, into major world regions of U.S., EU, Japan and rest of world (ROW), with drugs identified by active ingredient and brand name (in parentheses). It covers the major therapeutic indications for generic medicines:
Primary information for this report was gathered from numerous sources including in-person interviews and discussions, telephone interviews, and surveys, attendance at business presentations at healthcare technical and financial conferences as well as through secondary research. This market research study is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and the like. More than 200 detailed tables and figures provide key data about items such as revenues and market size, market share, segments and the like. This report includes 37 company profiles that provide the reader a snapshot of the companies' focus or activities. Internet links help readers access companies' own web sites for further review. Targeted Company:
Executive Summary 1. Global Market: Generic and Biogeneric Drugs 1.1 The Global Generic and Biogeneric Drug Landscape 1.1.1 Global Healthcare Spending 1.1.2 Global Prescription Volume for Generic and Biogeneric Drugs 1.1.3 Global Sales of Generic and Biogeneric Drugs 1.1.3.1 Global Sales of Generic and Biogeneric Drugs by Company Table 1.1: Sales by Company, 2008 Figure 1.1: Market Positions (Share) by Company, 2008 1.1.3.2 Global Sales of Generic and Biogeneric Drugs by Category 1.1.3.2.1 Allergy Drugs Table 1.2: Sales by Indication/Drug Name 2008 Figure 1.2: Market Positions (Share) by Drug Name, 2008 Table 1.3: Sales by Brand in $MM, 2008 - 2013 Figure 1.3: Sales by Brand, 2008 - 2013 1.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs Table 1.4: Sales by Indication/Drug Name, 2008 Figure 1.4: Market Positions (Share) by Drug Name, 2008 Table 1.5: Sales by Brand in $MM, 2008 - 2013 Figure 1.5: Sales Growth by Brand, 2008 - 2013 1.1.3.2.3 Anesthetics Table 1.6: Sales by Indication/Drug Name, 2008 Figure 1.6: Market Positions (Share) by Drug Name, 2008 Table 1.7: Sales of by Brand in $MM, 2008 - 2013 Figure 1.7: Sales Growth by Brand, 2008 - 2013 1.1.3.2.4 Anti-Convulsants Table 1.8: Sales by Indication/Drug Name, 2008 Figure 1.8: Market Positions (Share) by Drug Name, 2008 Table 1.9: Sales by Brand in $MM, 2008 - 2013 Figure 1.9: Sales Growth by Brand, 2008 - 2013 1.1.3.2.5 Anti-Infectives Table 1.10: Sales by Indication/Drug Name, 2008 Figure 1.10: Market Positions (Share) by Drug Name, 2008 Table 1.11: Sales by Brand in $MM, 2008 - 2013 Figure 1.11: Sales Growth by Brand, 2008 - 2013 1.1.3.2.6 Cancer Drugs Table 1.12: Sales by Indication/Drug Name, 2008 Figure 1.12: Market Positions (Share) by Drug Name, 2008 Table 1.13: Sales by Brand in $MM, 2008 - 2013 Figure 1.13: Sales Growth by Brand, 2008 - 2013 1.1.3.2.7 Cardiovascular Drugs Table 1.14: Sales of by Type/Drug Name, 2008 Figure 1.14: Market Positions (Share) by Drug Name, 2008 Table 1.15: Sales by Brand in $MM, 2008 - 2013 Figure 1.15: Sales Growth by Brand, 2008 - 2013 1.1.3.2.8 CNS and Psychotherapeutic Drugs Table 1.16: Sales by Type/Drug Name, 2008 Figure 1.16: Market Positions (Share) by Drug Name, 2008 Table 1.17: Sales by Brand in $MM, 2008 - 2013 Figure 1.17: Sales Growth by Brand, 2008 - 2013 1.1.3.2.9 Cholesterol Reducers/Statins Table 1.18: Sales by Type/Drug Name, 2008 Figure 1.18: Market Positions (Share) by Drug Name, 2008 Table 1.19: Sales by Brand in $MM, 2008 - 2013 Figure 1.19: Sales Growth by Brand, 2008 - 2013 1.1.3.2.10 Diabetes Drugs Table 1.20: Sales by Type/Drug Name, 2008 Figure 1.20: Market Positions (Share) by Drug Name, 2008 Table 1.21: Sales by Brand in $MM, 2008 - 2013 Figure 1.21: Sales Growth by Brand, 2008 - 2013 1.1.3.2.11 Gastrointestinal Drugs/Proton Pump Inhibitors Table 1.22: Sales by type/Drug Name, 2008 Figure 1.22: Market Positions (Share) by Drug Name, 2008 Table 1.23: Sales by Brand in $MM, 2008 - 2013 Figure 1.23: Sales Growth by Brand, 2008 - 2013 1.1.3.2.12 Hormonal Drugs Table 1.24: Sales by Type/Drug Name, 2008 Figure 1.24: Market Positions (Share) by Drug Name, 2008 Table 1.25: Sales by Brand in $MM, 2008 - 2013 Figure 1.25: Sales Growth by Brand, 2008 - 2013 1.1.3.2.13 Osteoporosis and Hypercalcemia Drugs Table 1.26: Sales by Type/Drug Name, 2008 Figure 1.26: Market Positions (Share) by Drug Name, 2008 Table 1.27: Sales by Brand in $MM, 2008 - 2013 Figure 1.27: Sales Growth by Brand, 2008 - 2013 1.1.3.2.14 Sleeping Agents Table 1.28: Sales by Type/Drug Name, 2008 Figure 1.28: Market Positions (Shape) by Drug Name, 2008 Table 1.29: Sales by Brand in $MM, 2008 - 2013 Figure 1.29: Sales Growth by Brand, 2008 - 2013 1.1.3.2.15 Other Drugs Table 1.30: Sales by Type/Drug Name, 2008 Figure 1.30: Market Positions (Share) by Drug Name, 2008 Table 1.31: Sales by Brand in $MM, 2008 - 2013 Figure 1.31: Sales Growth by Brand, 2008 - 2013 1.2 Growth Trends for Global Generics and Biogenerics Drug Market, 2008 - 2013 Table 1.32: R&D for Global Biogeneric Drugs by Compnay/R&D Activities/Expected Market Entry 1.3 Summary of Global Generics and Biogenerics Drug Market, 2008 - 2013 1.3.1 Global Sales of Generic and Biogeneric Drugs, 2008 - 2013 Table 1.33: Global Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013 1.3.2 Global Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013 Table 1.34: Global Prescription Volume for Generic and Biogeneric Drugs by Segment in Millions, 2008 - 2013 1.3.3 Issues, Sales Drivers and Restraints 2. U.S. Market: Generic and Biogeneric Drugs 2.1 The Generic and Biogeneric Drug Landscape in the U.S. 2.1.1 U.S Healthcare Spending and Patient Demographics 2.1.2 U.S Prescription Volume for Generic and Biogeneric Drugs 2.1.3 U.S Sales of Generic and Biogeneric Drugs 2.1.3.1 U.S. Sales of Generic and Biogeneric Drugs by Company Table 2.1: U.S. Sales of Generic and Biogeneric Drugs by Company, 2008 Figure 2.1: U.S. Market Positions (Share) of Manufacturers of Generic and Biogeneric Drugs by Company, 2008 2.1.3.2 U.S. Sales of Generic and Biogeneric Drugs by Category Common Research Item Table: Sales by Indication/Drug Name or Type/Drug Name, 2008 Figure: Market Positions (Shape) by Drug Name, 2008 Table: Sales by Brand in $MM, 2008 - 2013 Figure: Sales by Brand, 2008 - 2013 2.1.3.2.1 Allergy Drugs 2.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs 2.1.3.2.3 Anesthetics 2.1.3.2.4 Anti-Convulsants 2.1.3.2.5 Anti-Infectives 2.1.3.2.6 Cancer Drugs 2.1.3.2.7 Cardiovascular Drugs 2.1.3.2.8 CNS and Psychotherapeutic Drugs 2.1.3.2.9 Cholesterol Reducers/Statins 2.1.3.2.10 Diabetes Drugs 2.1.3.2.11 Gastrointestinal Drugs/Proton Pump Inhibitors 2.1.3.2.12 Hormonal Drugs 2.1.4.3.13 Osteoporosis and Hypercalcemia Drugs 2.1.4.3.14 Sleeping Agents 2.1.4.3.15 Other Drugs 2.2 Growth Trends for the U.S. Generics and Biogenerics Drug Market, 2008 - 2013 Table 2.31: R&D for U.S. Biogeneric Drugs by Compnay/R&D Activities/Expected U.S. Market Entry 2.3 Summary of U.S. Generics and Biogenerics Drug Market, 2008 - 2013 2.3.1 U.S. Sales of Generic and Biogeneric Drugs, 2008 - 2013 Table 2.32: U.S. Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013 2.3.2 U.S. Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013 Table 2.33: U.S. Prescription Volume for Generic and Biogeneric Drugs by Segement in Millions, 2008 - 2013 2.3.3 Issues, Sales Drivers and Restraints 3. European Market: Generic and Biogeneric Drugs 3.1 The Generic and Biogeneric Drug Landscape in the EU 3.1.1 EU Healthcare Spending and Patient Demographics 3.1.2 EU Prescription Volume for Generic and Biogeneric Drugs 3.1.3 EU Sales of Generic and Biogeneric Drugs 3.1.3.1 EU Sales of Generic and Biogeneric Drugs by Company Table 3.1: EU Sales of Generic and Biogeneric Drugs by Company, 2008 Figure 3.1: EU Market Positions (Share) of Manufacturers of Generic and Biogeneric Drugs by Company, 2008 3.1.3.2 EU Sales of Generic and Biogeneric Drugs by Category Common Research Item Table: Sales by Indication/Drug Name or Type/Drug Name, 2008 Figure: Market Positions (Shape) by Drug Name, 2008 Table: Sales by Brand in $MM, 2008 - 2013 Figure: Sales by Brand, 2008 - 2013 3.1.3.2.1 Allergy Drugs 3.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs 3.1.3.2.3 Anesthetics 3.1.3.2.4 Anti-Convulsants 3.1.3.2.5 Anti-Infectives 3.1.3.2.6 Cancer Drugs 3.1.3.2.7 Cardiovascular Drugs 3.1.3.2.8 CNS and Psychotherapeutic Drugs 3.1.3.2.9 Cholesterol Reducers/Statins 3.1.3.2.10 Diabetes Drugs 3.1.3.2.11 Gastrointestinal Drugs/Proton Pump Inhibitors 3.1.3.2.12 Hormonal Drugs 3.1.3.2.13 Osteoporosis and Hypercalcemia Drugs 3.1.3.2.14 Sleeping Agents 3.1.3.2.15 Other Drugs 3.2 Growth Trends for the EU Generics and Biogenerics Drug Market, 2008 -2013 Table 3.32: R&D for EU Biogeneric Drugs by Company/R&D Activities/Expected Market Entry 3.3 Summary of EU Generics and Biogenerics Drug Market, 2008 - 2013 3.3.1 EU Sales of Generic and Biogeneric Drugs, 2008 - 2013 Table 3.33: EU Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013 3.3.2 EU Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013 Table 3.34: EU Prescription Volume for Generic and Biogeneric Drugs by Segment in Millions, 2008 - 2013 3.3.3 Issues, Sales Drivers and Restraints 4. Japanese Market: Generic and Biogeneric Drugs 4.1 The Generic and Biogeneric Drug Landscape in Japan 4.1.1 Japan Healthcare Spending and Patient Demographics 4.1.2 Japan Prescription Volume for Generic and Biogeneric Drugs 4.1.3 Japan Sales of Generic and Biogeneric Drugs 4.1.3.1 Japan Sales of Generic and Biogeneric Drugs by Company Table 4.1: Japan Sales of Generic and Biogeneric Drugs by Company, 2008 Figure 4.1: Japan Market Positions (Share) of Manufacturers of Generic and Biogeneric Drugs by Company, 2008 4.1.3.2 Japan Sales of Generic and Biogeneric Drugs by Category Common Research Item Table: Sales by Indication/Drug Name or Type/Drug Name, 2008 Figure: Market Positions (Shape) by Drug Name, 2008 Table: Sales by Brand in $MM, 2008 - 2013 Figure: Sales by Brand, 2008 - 2013 4.1.3.2.1 Allergy Drugs 4.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs 4.1.3.2.3 Anti-Convulsants 4.1.3.2.4 Anti-Infectives 4.1.3.2.5 Cardiovascular Drugs 4.1.3.2.6 CNS and Psychotherapeutic Drugs 4.1.3.2.7 Cholesterol Reducers/Statins 4.1.3.2.8 Diabetes Drugs 4.1.3.2.9 Gastrointestinal Drugs/Proton Pump Inhibitors 4.1.3.2.10 Hormonal Drugs 4.1.3.2.11 Sleeping Agents 4.1.3.2.12 Other Drugs 4.2 Growth Trends for Japan Generics and Biogenerics Drug Market, 2008 - 2013 Table 4.25: R&D for Japanese Biogeneric Drugs by Company/R&D Activities/Expected Market Entry 4.3 Summary of Japan Generics and Biogenerics Drug Market, 2008 - 2013 4.3.1 Japan Sales of Generic and Biogeneric Drugs, 2008 - 2013 Table 4.26: Japan Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013 4.3.2 Japanese Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013 Table 4.27: Japan Prescription Volume for Generic and Biogeneric Drugs in Millions by Segment, 2008 - 2013 4.3.3 Issues, Sales Drivers and Restraints 5. Rest of World (ROW): Generic and Biogeneric Drugs 5.1 The Generic and Biogeneric Drug Landscape in the ROW 5.1.1 ROW Healthcare Spending and Patient Demographics 5.1.2 ROW Prescription Volume for Generic and Biogeneric Drugs 5.1.3 ROW Sales of Generic and Biogeneric Drugs 5.1.3.1 ROW Sales of Generic and Biogeneric Drugs by Company Table 5.1: ROW Sales of Generic and Biogeneric Drugs by Company, 2008 Figure 5.1: ROW Market Positions of Manufacturers of Generic and Biogeneric Drugs by Company, 2008 5.1.3.2 ROW Sales of Generic and Biogeneric Drugs by Category Common Research Item Table: Sales by Indication/Drug Name or Type/Drug Name, 2008 Figure: Market Positions (Shape) by Drug Name, 2008 Table: Sales by Brand in $MM, 2008 - 2013 Figure: Sales by Brand, 2008 - 2013 5.1.3.2.1 Allergy Drugs 5.1.3.2.2 Analgesics, NSAIDs and Antirheumatic Drugs 5.1.3.2.3 Anesthetics 5.1.3.2.4 Anti-Convulsants 5.1.3.2.5 Anti-Infectives 5.1.3.2.6 Cancer Drugs 5.1.3.2.7 Cardiovascular Drugs 5.1.3.2.8 CNS and Psychotherapeutic Drugs 5.1.3.2.9 Cholesterol Reducers/Statins 5.1.3.2.10 Diabetes Drugs 5.1.3.2.11 Gastrointestinal Drugs/Proton Pump Inhibitors 5.1.3.2.12 Hormonal Drugs 5.1.3.2.13 Osteoporosis and Hypercalcemia Drugs 5.1.3.2.14 Sleeping Agents 5.1.3.2.15 Other Drugs 5.2 Growth Trends for the ROW Generics and Biogenerics Drug Market by Company/R&D Activities/Expected Market Entry, 2008 - 2013 Table 5.31: R&D for ROW Biogeneric Drugs 5.3 Summary of ROW Generics and Biogenerics Drug Market, 2008 - 2013 5.3.1 EU Sales of Generic and Biogeneric Drugs, 2008 - 2013 Table 5.32: ROW Sales of Generic and Biogeneric Drugs by Segment in $MM, 2008 - 2013 5.3.2 ROW Prescription Volume for Generic and Biogeneric Drugs, 2008 - 2013 Table 5.33: ROW Prescription Volume for Generic and Biogeneric Drugs by Segment in Millions, 2008 - 2013 5.3.3 Issues, Sales Drivers and Restraints 6. Activities of Generic and Biogeneric Drug Makers Common Research Item -Profile -Contact -URL -Sales 2008 -Generic and Biogeneric Drug Sales 2008 -Generic Drug Categories 6.1 ~ 6.37 (Total 37 Companies) 7. Appendix 7.1 Selected Companies Mentioned in this Report Table 7.1: Major Generic and Biogeneric Companies FOR ORDER OR INQUIRY, PLEASE CLICK "ORDER / INQUIRY FORM" |